Merck Begin Period Cash Flow vs Change Receivables Analysis
MRK Stock | USD 131.10 0.34 0.26% |
Merck financial indicator trend analysis is infinitely more than just investigating Merck Company recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Merck Company is a good investment. Please check the relationship between Merck Begin Period Cash Flow and its Change Receivables accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Begin Period Cash Flow vs Change Receivables
Begin Period Cash Flow vs Change Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Merck Company Begin Period Cash Flow account and Change Receivables. At this time, the significance of the direction appears to have no relationship.
The correlation between Merck's Begin Period Cash Flow and Change Receivables is 0.02. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Change Receivables in the same time period over historical financial statements of Merck Company, assuming nothing else is changed. The correlation between historical values of Merck's Begin Period Cash Flow and Change Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Merck Company are associated (or correlated) with its Change Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change Receivables has no effect on the direction of Begin Period Cash Flow i.e., Merck's Begin Period Cash Flow and Change Receivables go up and down completely randomly.
Correlation Coefficient | 0.02 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most indicators from Merck's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Merck's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.18 this year, although the value of Tax Provision will most likely fall to about 2.2 B.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 35.1B | 41.9B | 43.9B | 46.1B | Total Revenue | 48.7B | 59.3B | 59.9B | 32.5B |
Merck fundamental ratios Correlations
Click cells to compare fundamentals
Merck Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Merck fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 84.4B | 91.6B | 105.7B | 109.2B | 106.7B | 60.3B | |
Short Long Term Debt Total | 26.3B | 31.8B | 33.1B | 30.7B | 36.3B | 38.1B | |
Other Current Liab | 14.9B | 16.3B | 16.9B | 18.0B | 15.5B | 16.3B | |
Total Current Liabilities | 22.2B | 27.3B | 23.9B | 24.2B | 25.7B | 13.3B | |
Total Stockholder Equity | 25.9B | 25.3B | 38.2B | 46.0B | 37.6B | 25.5B | |
Property Plant And Equipment Net | 15.1B | 18.0B | 19.3B | 21.4B | 24.5B | 25.7B | |
Net Debt | 16.7B | 23.7B | 25.0B | 18.0B | 29.4B | 30.8B | |
Retained Earnings | 46.6B | 47.4B | 53.7B | 61.1B | 53.9B | 32.6B | |
Cash | 9.7B | 8.1B | 8.1B | 12.7B | 6.9B | 5.6B | |
Non Current Assets Total | 56.9B | 63.8B | 75.4B | 73.4B | 74.5B | 41.1B | |
Non Currrent Assets Other | 5.3B | 9.2B | 8.1B | 7.7B | 9.2B | 6.1B | |
Cash And Short Term Investments | 10.5B | 8.1B | 8.1B | 13.2B | 7.2B | 7.3B | |
Net Receivables | 6.8B | 7.9B | 9.2B | 9.5B | 11.1B | 11.6B | |
Common Stock Shares Outstanding | 2.6B | 2.5B | 2.5B | 2.5B | 2.5B | 2.7B | |
Liabilities And Stockholders Equity | 84.4B | 91.6B | 105.7B | 109.2B | 106.7B | 60.3B | |
Non Current Liabilities Total | 36.2B | 38.9B | 43.6B | 38.9B | 43.3B | 45.5B | |
Inventory | 6.0B | 6.3B | 6.0B | 5.9B | 6.4B | 3.7B | |
Other Current Assets | 4.3B | 5.5B | 7.0B | 7.2B | 7.6B | 8.0B | |
Other Stockholder Equity | (16.3B) | (17.2B) | (12.9B) | (12.1B) | (12.9B) | (12.3B) | |
Total Liab | 58.4B | 66.2B | 67.4B | 63.1B | 69.0B | 72.5B | |
Total Current Assets | 27.5B | 27.8B | 30.3B | 35.7B | 32.2B | 19.2B | |
Short Term Debt | 3.6B | 6.4B | 2.4B | 1.9B | 1.7B | 2.3B | |
Intangible Assets | 14.2B | 14.6B | 22.9B | 20.3B | 18.0B | 14.3B | |
Accounts Payable | 3.7B | 4.6B | 4.6B | 4.3B | 3.9B | 2.8B | |
Property Plant And Equipment Gross | 15.1B | 18.0B | 37.5B | 39.4B | 41.3B | 43.4B | |
Accumulated Other Comprehensive Income | (6.2B) | (6.6B) | (4.4B) | (4.8B) | (5.2B) | (4.9B) | |
Short Term Investments | 774M | 1M | 0.0 | 498M | 252M | 239.4M | |
Other Liab | 12.7B | 12.1B | 11.7B | 9.1B | 10.5B | 10.2B | |
Other Assets | 5.3B | 7.8B | 9.4B | 7.4B | 8.5B | 5.5B | |
Long Term Debt | 22.7B | 25.4B | 30.7B | 28.7B | 33.7B | 17.2B | |
Good Will | 19.4B | 20.2B | 21.3B | 21.2B | 21.2B | 12.3B | |
Treasury Stock | (56.0B) | (56.8B) | (57.1B) | (56.5B) | (57.5B) | (54.6B) | |
Property Plant Equipment | 15.1B | 18.0B | 19.3B | 21.4B | 24.6B | 16.2B | |
Net Tangible Assets | (7.7B) | (9.5B) | 3.5B | 4.5B | 4.1B | 4.5B | |
Noncontrolling Interest In Consolidated Entity | 94M | 87M | 73M | 67M | 54M | 51.3M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Merck Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.685 | Dividend Share 2.96 | Earnings Share 0.9 | Revenue Per Share 24.215 | Quarterly Revenue Growth 0.089 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.